209 related articles for article (PubMed ID: 33854618)
1. Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.
Wang Y; Xiu J; Ren C; Yu Z
J Cancer; 2021; 12(9):2570-2581. PubMed ID: 33854618
[TBL] [Abstract][Full Text] [Related]
2. PIM Kinase as an Executional Target in Cancer.
Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
[TBL] [Abstract][Full Text] [Related]
3. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
[TBL] [Abstract][Full Text] [Related]
4. Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.
Katsuta E; Gil-Moore M; Moore J; Yousif M; Adjei AA; Ding Y; Caserta J; Baldino CM; Lee KP; Gelman IH; Takabe K; Opyrchal M
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 35920189
[TBL] [Abstract][Full Text] [Related]
5. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
Nair JR; Caserta J; Belko K; Howell T; Fetterly G; Baldino C; Lee KP
Leukemia; 2017 Aug; 31(8):1715-1726. PubMed ID: 28008178
[TBL] [Abstract][Full Text] [Related]
6. Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Chulanetra M; Seesuay W; Chaicumpa W; Sookrung N
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770845
[TBL] [Abstract][Full Text] [Related]
7. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression.
Kronschnabl P; Grünweller A; Hartmann RK; Aigner A; Weirauch U
Int J Oncol; 2020 Feb; 56(2):448-459. PubMed ID: 31894300
[TBL] [Abstract][Full Text] [Related]
10. Pim2 is important for regulating DNA damage response in multiple myeloma cells.
Ramachandran J; Santo L; Siu KT; Panaroni C; Raje N
Blood Cancer J; 2016 Aug; 6(8):e462. PubMed ID: 27564460
[TBL] [Abstract][Full Text] [Related]
11. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
Atalay P; Ozpolat B
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
[TBL] [Abstract][Full Text] [Related]
12. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
Burger MT; Han W; Lan J; Nishiguchi G; Bellamacina C; Lindval M; Atallah G; Ding Y; Mathur M; McBride C; Beans EL; Muller K; Tamez V; Zhang Y; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Holash J; Castillo J; Langowski J; Wang Y; Chen MY; Garcia PD
ACS Med Chem Lett; 2013 Dec; 4(12):1193-7. PubMed ID: 24900629
[TBL] [Abstract][Full Text] [Related]
13. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
Haas M; Caron G; Chatonnet F; Manenti S; Alaterre E; Devin J; Delaloy C; Bertolin G; Viel R; Pignarre A; Llamas-Gutierrez F; Marchalot A; Decaux O; Tarte K; Delpy L; Moreaux J; Fest T
Blood; 2022 Apr; 139(15):2316-2337. PubMed ID: 35108359
[TBL] [Abstract][Full Text] [Related]
14. PIM Kinases in Multiple Myeloma.
Wu J; Chu E; Kang Y
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
[TBL] [Abstract][Full Text] [Related]
15. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
16. PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.
Ren C; Yang T; Qiao P; Wang L; Han X; Lv S; Sun Y; Liu Z; Du Y; Yu Z
Mol Oncol; 2018 May; 12(5):690-704. PubMed ID: 29570932
[TBL] [Abstract][Full Text] [Related]
17. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
18. Proviral insertion in murine lymphomas 2 promotes stomach cancer progression by regulating apoptosis via reactive oxygen species-triggered endoplasmic reticulum stress.
Xin H; Deng Y; Cao J
Biochem Biophys Res Commun; 2018 Nov; 506(1):145-152. PubMed ID: 30340823
[TBL] [Abstract][Full Text] [Related]
19. Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
Adam K; Lambert M; Lestang E; Champenois G; Dusanter-Fourt I; Tamburini J; Bouscary D; Lacombe C; Zermati Y; Mayeux P
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26500282
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer.
Han X; Ren C; Yang T; Qiao P; Wang L; Jiang A; Meng Y; Liu Z; Du Y; Yu Z
Oncogene; 2019 Sep; 38(38):6537-6549. PubMed ID: 31358902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]